Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
More than 120 speakers and 5,000 delegates are expected to attend
Arizona-based, leading medical devices company, Confluent Medical Technologies, will be establishing a pilot manufacturing facility in Hyderabad.
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Subscribe To Our Newsletter & Stay Updated
